Arnaud PIGNEUX
University Hospital, Bordeaux · French Innovative Leukemia Organization · FILO (French Innovative Leukemia Organization)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arnaud PIGNEUX as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:53 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07463768 · Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.French Innovative Leukemia Organisation · not yet recruiting · Acute Myeloid Leukemia · principal investigator
- N/ANCT06891144 · Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia (AML) and Receiving Intensive Induction TherapyFrench Innovative Leukemia Organisation · recruiting · AML, Adult · study chair
- Ph2NCT04968015 · Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First RemissionFrench Innovative Leukemia Organisation · active not recruiting · Acute Myeloid Leukemia · principal investigator
- Ph2NCT03603795 · Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction ChemotherapyFrench Innovative Leukemia Organisation · unknown · Acute Myeloid Leukemia · principal investigator
- Ph3NCT00700544 · Treatment Outcome in Elderly PatientsUniversity Hospital, Grenoble · completed · AML, Elderly Patients · principal investigator
- Ph3NCT00590837 · Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years OldUniversity Hospital, Bordeaux · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT00419081 · Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensBioCryst Pharmaceuticals · terminated · Leukemia, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:53 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:53 UTC. The ranking covers the 200 most relevant of 59 PubMed records, and a shared surname and initials can bring in a namesake. All 59 on PubMed
- 1,254 citationsRCR 40.6
- 317 citationsRCR 8.4
- 256 citationsRCR 5.4
- International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.J Clin Oncol · 2014169 citationsRCR 4.9
- 137 citationsRCR 4.3
- 134 citationsRCR 4.6
- Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.J Clin Oncol · 2006128 citationsRCR 2.8
- 128 citationsRCR 4.1
- Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.Lancet Haematol · 2023108 citationsRCR 8.5
- 106 citationsRCR 8.3